Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD

Welcome to OncLive On Air®! I’m your host today, Jax DiEugenio.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Connie Lai, MD, a medical oncology resident at Queen Elizabeth Hospital in Hong Kong, about a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer (mCRC).

In our exclusive interview, Dr Lai discussed how this study addressed the ongoing lack of consensus regarding whether patients with mCRC should continue maintenance therapy or take a treatment break following induction chemotherapy. She detailed the study’s methodology, including propensity score–matched analyses comparing patients who received maintenance therapy with those who paused treatment, as well as the key findings demonstrating superior overall and progression-free survival with maintenance therapy. Dr Lai also highlighted subgroup observations suggesting enhanced benefit among patients with more than 3 metastatic sites, and she reflected on the implications of these findings in the modern treatment era, particularly in the context of monoclonal antibody use.

____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.